Duloxetine Delayed-Release Capsules
Recall D-0277-2025, part of FDA recall event 96427. See Rising Pharma Holdings's company page.
Rising Pharma Holding, Inc. started this Class II drug recall on Mar 5, 2025 (voluntary: firm initiated); FDA lists it as ongoing.
- Classification: Class II
- Started: Mar 5, 2025
- Status: Ongoing
CGMP Deviations: Presence of N-nitroso-duloxetine impurity above recommended interim limit.
- Product
- Duloxetine Delayed-Release Capsules, USP, 30 mg, 1,000-count bottle, Rx only, Distributed by: Rising Health, LLC, Saddle Brook, NJ 07663, NDC 57237-018-99
- Quantity
- 1223 bottles
- Lots and codes
- Lot #: DTB23111A, Exp 8/31/2025
- Distribution
- Nationwide in the USA.
- Recalling firm
- Rising Pharma Holding, Inc., East Brunswick, NJ, United States
- How the firm notified
- Letter
- FDA classified
- Mar 14, 2025
Newest first, one product per recall event; search them all
- Rising, Cyproheptadine Hydrochloride Syrup, 2mg/5 mL, 473 mL (ONE PINT), Rx only, Manufactured for: Rising Pharma…D-0724-2026 · Class II · Jul 13, 2026 · Ongoing
- Product label: Temozolomide Capsules, 5mg, packaged in 5-capsule bottles, Rx only, Manufactured for: Rising…D-0384-2026 · Class II · Mar 3, 2026 · Ongoing
- Carbidopa, Levodopa, Entacapone Tablets, 25 mg/100 mg/200 mg, 100-count bottle, Rx Only, Manufactured for: Rising…D-0029-2026 · Class II · Oct 7, 2025 · Ongoing
- Duloxetine Delayed-Release Capsules USP 20 mg, 60 count bottles, Rx only, Distributed by: Rising Pharm Holdings, Inc.,…D-0189-2025 · Class II · Dec 30, 2024 · Ongoing
- Duloxetine Delayed-Release Capsules USP, 20 mg, 60 count bottles, Rx only, Distributed by: Rising Pharma Holdings,…D-0105-2025 · Class II · Nov 19, 2024 · Ongoing
- Diflorasone Diacetate Ointment, USP, 0.05%, 60g tube, Rx only, Mfd. By: Lyne Laboratories, Inc., Brockton, MA 02301;…D-0599-2024 · Class III · Jun 24, 2024 · Ongoing
- Pregabalin Capsules 50mg, 1000-count bottle, Rx Only, Manufactured for: Rising Pharma Holdings, Inc., East Brunswick,…D-0541-2024 · Class III · May 16, 2024 · Ongoing
FDA's weekly Enforcement Report, as openFDA publishes it. A recall is classified by how likely the product is to cause harm: Class I is the most serious. openFDA drug enforcement reports